Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
DEINOVELife genius delivered
1
PROFILELife genius delivered
2
Disruptive innovationTO ANSWER HEALTH AND ENVIRONMENTAL CHALLENGES
BioactivesActive ingredients of natural origin for cosmetics and nutrition
Next-generation anti-infectives to fight antimicrobial resistance
Antibiotics
Innovative molecules from rare and extremophilic microorganisms
Lead generation platform
Life genius delivered
3
FOUNDED IN
2006BASED IN MONTPELLIER 62 HIGHLY-
SKILLED STAFF310 PATENTS WORLDWIDE
LISTED IN PARIS
SINCE 20101,500 M2
LAB FACILITIES
A cutting-edge biotechnology platform
Biodiversity BioInformatics Fermentation Extraction & purification
Genetic engineering Analytics Screening
INNOVATIVE, ECO-FRIENDLY, ACTIVE MOLECULES FROM CONCEPTION TO PRODUCTION
4
Exclusive 6,000+
rare strains collection Understanding the metabolic pathways
Developing efficient production processes
Isolating and formulating molecules for their final use
Guiding and optimizing the production of molecules
Controlling production process and product characteristics
Functional activities testing
BIOACTIFS
Phyt-N-Resist®Phytoene (colorless carotenoid) Proprietary asset
Hebelys®With Greentech
Innovative CarotenoidProprietary asset
Oléos 1 & 2With Oléos-Hallstar
COLOR2BWith Avril
DNV 3837Active againstClostridium difficile
AGIR
Preclinical
Severe gastro-intestinal infections
Phase I Phase II Phase III
Discovery platform for novel antibiotic structures
Programs under development
Anti-aging cosmetic ingredient
Anti-aging cosmetic ingredient
Cosmetic active ingredients
Natural feed additives
Research DevelopmentIndustrial scale-up
Market
Cosmetic active ingredient
Bioactives
Antibiotics
5
ANTIBIOTICSNext-generation anti-infectives to fight antimicrobial resistance
6
The challenge of AntiMicrobial Resistance (AMR)A MAJOR THREAT FOR HUMANITY
Source: Revue on antimicrobial resistance
A global health challenge
FIND NOVEL ANTIBIOTIC STRUCTURES TO FIGHT RESISTANT PATHOGENSIS AN URGENT NEED
«Antimicrobial resistance is a slow-motion tsunami
that must be managed with the utmost urgency.»
Dr. Margaret Chan, Director-General of WHO, Sept.2016
7
700,000DEATHS / YEARTODAY
10 millionsDEATHS / YEARIN 2050
A risk for the world economy$100
TRILLIONS
LOSS OF ECONOMIC OUTPUT WORTH BY 2050
Healthcare costs
Challenging the ability to continue performing daily medical procedures
(transplantations, chemotherapy...)
Platform dedicated to the exploration of rare microorganismsand identification of novel antibiotic structures
Discovery Platform
8
AGIR (=“ACT”) : ANTIBIOTICS AGAINST RESISTANT INFECTIOUS GERMS
AGIR Antibiotiquescontre les GermesInfectieux Résistants
A FIRST NCE DISCOVEREDDNB101/102Published in Nature Chemical Biology
Two patent applications
€14.6 MFrench Government funding
RESEACH COLLABORATIONS Access to new strains
BIODIVERSITYProprietary library of 6,000 extremophilic strains
Development of the automated
discovery platform
Lead optimization and process development
Production of molecules with optimal
performances
Bacteria Antibiotics
DNV3837 antibiotic candidate ready to enter Phase II
9
TARGETING SEVERE CLOSTRIDIUM DIFFICILE INFECTIONS (CDI)
FREQUENCY
RECURRENCE
MORTALITYDesignated as an URGENT threat by the CDC
(American Centers for Disease Control and Prevention)
CLOSTRIDIUM DIFFICILEAntibiotic-resistant spore-forming
bacterium that colonizes the intestine
Sources:U.S. Centers for Disease Control: Antibiotic Resistance Threats in the United States, 2013. Desai et al., BMC Infectious Diseases 2016; 16. Decision Resources: Treatment trends, C. diff Infections (US) 2012; (EU) 2013
CDI are currently two to four times more common than Hospital Acquired Diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) which have been a leading public health concern for many years
~20% re-admission within 30 days
Steadily increasing, as a result of the development of highly virulent strains
40% of patients suffer from a severe form
35-50% : mortality rate of patients with severe CDI with complications (megacolon, perforation)
CLOSTRIDIUM DIFFICILE INFECTIONS
Clostridium difficile Infections (CDI)A FAST-EXPANDING DISEASE, A REAL THERAPEUTIC NEED
10
INCIDENCE OF CDI (THOUSANDS OF CASES) +27%
364411
481
662
2012 2021
EUROPE USA
845
1,073
GROWING ISSUE
INCREASED AWARENESS
SIGNIFICANT IMPACT
AGEING POPULATIONIncreasing number of people in long term care (LTC) facilities
Increasing number of beds per hospital/LTC facility
UNDER-ESTIMATED DIAGNOSISAbsence of clinical suspicion
Suboptimal diagnosis methods
Unreported cases due to the embarrassing nature of illness
HUMAN AND ECONOMIC COSTUSA: 44,500 deaths / year Europe: 3,700 deaths / year Economic Impact: $10 B / year
Sources: Decision Resources: Treatment Trends C. diff. Infections (EU) 2013. Davies et al. LID 2014. LESSA ET AL., 2015. MORPHOCHEM.
DNV3837A POSSIBLE EFFECTIVE THERAPEUTIC OPTION
11
FAST TRACK STATUS& QIDP DESIGNATION granted by FDA
READY TO ENTERPHASE IIScheduled for mid-2019Multicentric trial
3 CONCLUSIVE PHASE I TRIALS• ≈ 100 healthy volunteers• Very targeted activity• Acceptable tolerance profile
1ST LINE TREATMENTof severe Clostridium difficile infections
Only 2 oral drugs approved for treatment of CDI: vancomycin & fidaxomicin
Ineffective in severe cases (facing colitis, intestinal paralysis....)
No approved IV treatment available, off-label metronidazole does not reduce mortality
TREATMENT BY INTRAVENOUS INJECTION
Easier to administer in severe casesMore efficient
DNV3837
12
A NOVEL ANTIBIOTIC CLASS
PRESERVES THE GUT MICROBIOTE• Reduces viable counts of Gram-positive
anaerobic bacteria (C.difficile)• Does not affect Gram-negative microflora
Bacterial concentration in stoolC. diff. vs Gram-negative flora
single subjects
log10
CFU/
g fec
es
Pre-dose Last day of Day 7 of infusion (Day 5) post-exposure
ClostridiaeBacteroides
DNV3837• New class of small molecule:
quinolonyl-oxazolidinone • Powerful inhibitor of ribosomal translation
and DNA gyrase• Interact with topoisomerase IV • Down-regulates two T-RNA synthetases
N
FO
OH
O
NO
F
NO
NH
O
OOPO
OOH Na+
DNV3837
13
IV TREATMENT EFFECTIVE AGAINST GASTRO-INTESTINAL INFECTIONS
Vancomycin Metronidazole Fidaxomicin DNV3837
mg/
L
0.0
0.5
1.0
1.5
2.0
Antibiotic activity against C. difficile(MIC90, range ; 114 clinical isolates)
0.5
1
0.125 0.064
Pre-dose
mg
/ kg
fece
s
50
100
150
200
High fecal concentration of the drug after IV administration
117 ± 92
250
Day 2 Last day of infusion
0
171 ± 43
SUPERIOR EFFICACY• Superior to reference treatments
against 114 different isolates of C. difficile• Including the highly virulent NAP1 strain
TARGETED ACTIVITY• High drug concentration in stool (site of
infection)• Fecal concentration exceeds by far MIC90
(minimum concentration to inhibit 90% growth of pathogenic strains)
DNV3837CLINICAL DEVELOPMENT PROGRAM
14
MULTICENTRIC INTERNATIONAL PHASE II MID-2019
SCHEDULED FOR
10-12 MONTHSDuration of study
~40 PATIENTS2 cohorts : moderate and severe
15 CLINICAL CENTRESGermany (5)USA (10)
DEINOVE CHOSE MEDPACE AS A CROSupport for the design and supervision of the clinical trialData collection and analysisInteractions with the FDA
BIOACTIVESActive ingredients of natural origin for cosmetics and nutrition
15
The 1st 100% DEINOVE-made activeAN INNOVATIVE AND DIFFERENTIATED ANTI-AGING INGREDIENT
16
SCIENTIFICALLY PROVEN• in vitro / ex vivo testing
•Proven clinical benefits
PREMIUM •100% pure
molecule
•Highly concentrated
MULTI-APPLICATION•Antioxidant ++
•Skin renewal
ACTIVE INGREDIENTInnovative Carotenoid
Phyt-N-ResistTHE FIRST PURE PHYTOENE
ECO-FRIENDLY•Bioproduction•From natural sugars•Reproducible process
Deinococcus: bacteria hyper-resistant to extreme conditions: heat, drought, radiation…
Deinobased
PATENTEDTECHNOLOGY
ENHANCED SKIN REGENERATION AND HEALINGTARGETED ANTIOXIDANT PROTECTION
VISIBLE ANTI-AGING BENEFITS
Phyt-N-Resist®PROVEN CLINICAL BENEFITS
17
FIRMNESSX2
ELASTICITYX3 as of 28 days
-17% WRINKLES DEPTH
RADIANCE
D0 D28 D56
PROMOTES COMPLETE SKIN REGENERATION after 14 days vs 20 days under natural conditionsIn vivo DHA Test
– 80%LIPID OXIDATIONvs untreated explantsEx vivo tests ACCELERATES
SKIN REPAIRIn vitro tests
An outsourced and diversified distribution strategyWORLDWIDE DISTRIBUTION AGREEMENTS
Marketing agreementReGeN-oPhyt®
North America and Asia Distribution agreementPhyt-N-Resist®
EMEA
1 Source L’Oréal
18
37%Asia-Pacific
18%Western Europe
11%Latin America
6%Eastern Europe
25%North America
WORLDWIDE SALES OF COSMETIC PRODUCTS
3%Africa, ME
€200 B WORLD COSMETIC MARKET1
+ 4 to 5% PER YEAR
37% SKINCARE
Marketing agreementReGeN-oPhyt®
North America and Asia
HEBELYS, DEVELOPED WITH GREENTECH
Anti-aging active for mature skin
An expanding portfolio of assetsFULLY-OWNED AND CO-DEVELOPED
19
A 2ND 100% DEINOVE-MADE ACTIVE IN DEVELOPMENTa dermocosmetic indication showing strong growth
Major player in the production and distribution of biotechnologically derived ingredientsSells a hundred active ingredients derived from biodiversity to cosmetics manufacturers in over 30 countries
2018LAUNCHED IN
TWO INGREDIENTS IN DEVELOPMENT100% natural cosmetic actives with OLÉOS
Part of the American group HALLSTARProprietary Oleo-Eco-Extraction technology Has already developed twenty or so active ingredients marketed to cosmetics brands in France and abroad
2019/2020SCHEDULED FOR
2019LAUNCH SCHEDULED
FOR
A catalogue of qualified active extractsMULTIPLE OPPORTUNITIES FOR COLLABORATION
Aloh’age®
Antioxidant HealingTahiti
Arenactive®
AntioxidantHealingAnti-inflammatoryMediterranean beach
Tropicalis®
AntioxidantLa Réunion island
Luccamine®
AntioxidantHealingAnti-inflammatory Corsica
Luminaris®
Antioxidant WhiteningCanary Islands
DOZENS OF RARE STRAINS…
20
ANTIOXIDANTAnti-aging, anti-UV…
HEALINGAnti-aging, damaged skin…
LIPID STORAGEPlumping, moisturizing…
ANTI-INFLAMMATORYSensitive / irritated skin
Post-operative skin care…
LIPOLYSISSlimming, Anti-cellulite…
WHITENINGLightening/brightening, Anti-blemish…
… WITH CONFIRMED COSMETIC PROPERTIES
Example of a bacterial extract availableANTIOXIDANT AND HEALING PROPERTIES
21
ClaimsFEATURES• Sample source: Taravao, Tahiti
• Type of sample: vegetal (lichen)
• Isolation temperature: 45°C
Aloh’age INNOVATIVE AND NATURAL ACTIVE EXTRACT
ANTIOXIDANT AND HEALING PROPERTIES
EXTREMOPHILIC MICROORGANISM
DOSE-EFFECTACTIVITY
ANTI-AGING
UV PROTECTION
DAMAGED SKIN
POST-OPERATION TREATMENT
Healing testin vitro
Oxidation testin vitro
COLOR2BNATURAL FEED ADDITIVES
SCREENING OF THE STRAIN LIBRARY
SELECTION AND EVALUATION OF STRAINS OF POTENTIAL INTEREST
CHARACTERIZATION OF THE MOLECULES PRODUCED, OPTIMIZATION OF PRODUCTION CONDITIONS
DEMONSTRATED EFFECTIVENESS IMPROVING OPTIMAL DOSAGE
NEXT STEPSIndustrialization of productionRegulatory pathwayLicense agreementLaunch of new animal nutrition products
OBJECTIVE: TO LAUNCH A NEW RANGE OF NATURAL PRODUCTSAvril, a key player in the French oil and protein sectorDevelopment of a natural alternative to petroleum-based ingredientsProject co-financed by both partners
22
Business model BioactivesREACHING THE COMMERCIALIZATION STAGE
23
• COMPOUNDS DEVELOPED IN-HOUSE• TOLL MANUFACTURING• DISTRIBUTION VIA INGREDIENTS
SUPPLIERS / SALES PER KG
DIRECT MARKETING
• R&D COLLABORATIONS• TECHNOLOGY LICENSES• ROYALTIES ON SALES
INDUSTRIAL PARTNERSHIPS
GENERATE
SHORT-TERM
INCOME
CORPORATE PROFILEManagement and financial data
24
The DEINOVE stock
25
EURONEXT GROWTH PARIS
MARKET CAPITALIZATION
LISTED IN PARIS
SINCE 2010ISIN
FR001087905615.8mTRADABLE SHARES
€ 23m MARKET CAP
125,000 SHARES / DAY
€1.48SHARE PRICE AS AT 28.02.19
0
10
20
30
40
50
60
janv-18 avr-18 juil-18 oct-18 janv-19
11.28%Funds managed by Truffle Capital
0.54%Management
0.25%Scientific founders(M. Radman, Université P. Descartes)
80.83%Free float
7.11%Funds managed
by TVM Capital
BREAKDOWN OF SHARE CAPITAL as at 31 December 2018 (non diluted basis)
BROKER TARGET DATE
Arrowhead €4.6 26.09.18
Edison €4.0 04.04.18
Midcap partners €4.3 15.05.18
Invest Securities €5.2 01.10.18
Financial data – FY 2018
26Confidential
• Vs -€7.3m in 2017
• Operating revenues +€0,8m (vs €0.2m in 2017)
• Operating costs (€11.2m), 76% of which are R&D expenses
NET RESULT: -€8.7m
• Vs +€4.9m as at 31.12.17
• Cash-out: operating expenses (€10.4m) ; investments (€1.9m)
• Cash-in: capital increase (€8.0m) ; equity line (€0.7m) ; public grants (€2.6m)
• Post-closing Cash-in: R&D tax credit (€2.5m) ; AGIR - 1st instalment (€1.5m)
CASH POSITION 31.12.18: +€3.9m
Provides the resources required until Q2 2020, using the equity line
MANAGEMENTAN EXPERIENCED TEAM
Coralie MartinHead of Communication, Marketing and Investor Relations
Johane Rinaldi Head of HR
Emmanuel PetiotCEO
Julien CosteDirector of Finance & Administration
Georges GaudriaultScientific Director
Marie BézengerDirector of Operations
Sébastien Enault Head of Business Development
27
A high-level board of directorsPROVEN EXPERIENCE IN HEALTH AND BIOTECH
28
Philippe POULETTYFounder of Truffle Capital Founder of SangStat acquired by Genzyme for 600M$
Charles WOLER, ChairmanFormerly Chairman and CEO of Roche FranceChairman of Genfit & GSK Europe
Vincent JARLIERHead of Bacteriology Department, Pitié-Salpétrière HospitalFounder & President of ONERBA (National observatory for epidemiology of bacterial resistance to antibiotics)
Hervé BRAILLYCo-founder & Chairman of Supervisory Board at Innate Pharma
Yannick PLÉTANChief medical officer, Head of clinical R&D and medical affairs at Acticor Biotech
Anne ABRIAT-HEMMENDINGERFounder of The Smell & Taste LabFormerly Product development and marketing for L’Oréal and Coty
Investment highlights
29
DISRUPTIVEA pioneer biotechnology company producing innovative and naturally-sourced active molecules based on a unique collection of rare microorganisms and cutting-edge technological platform
LATE-STAGE CLINICAL DEVELOPMENTThe DNV3837 program: launch of Phase II of a first-in-class antibiotic targeting an unmet medical need for severe Clostridium difficile infections
DIVERSIFIEDA diversified portfolio of innovative
compounds for applications in three markets with high added value:
Cosmetics, Health and Nutrition
COMMERCIAL STAGEDe-risked technology
Two products already on the market
SUCCESSFUL STRATEGIC MOVE
30
CONTACTS
MONTPELLIER, FRANCECAP SIGMA - ZAC Euromédecine II1682 rue de la Valsière 34790 GRABELS
www.deinove.com
Emmanuel PETIOTCEOPh: + 33 6 13 80 25 [email protected]
Coralie MARTINCommunication, Marketing and Investor relations managerTel.: + 33 4 48 19 01 [email protected]
APPENDICES
31
Business model AntibioticsA SECTOR OF ACTIVITY ELIGIBLE FOR NON-DILUTIVE FUNDING TO SUPPORT RESEARCH
• PUBLIC RESEARCH SUPPORT PROGRAMMES
• ACCELERATED APPROVAL PROCEDURES AND EXTENSION OF INDUSTRIAL PROTECTION PERIODS
• MANY PRIVATE INITIATIVES
STATE / INSTITUTIONAL SUPPORT
• R&D COLLABORATIONS
• LICENSING AGREEMENTS / RIGHTS GRANTING ON MOLECULES
INDUSTRIAL PARTNERSHIPS
32